



FIG. 1



LSD

FIG. 2



Ketanserin

FIG. 3




FIG. 4 Duration of LSD + Ketanserin




FIG. 5A




FIG. 5B





FIG. 5C



SUBSTITUTE SHEET (RULE 26)

FIG. 5D




FIG. 5E





FIG. 5F



SUBSTITUTE SHEET (RULE 26)

FIG. 5G




FIG. 5H





FIG. 5I






FIG. 7A

Mean values and statistics for the acute effects of LSD alone, LSD + ketanserin, and placebo.

		Placebo	LSD 25 µg	LSD 50 µg	LSD 100 µg	LSD 200 µg	LSD 200 µg + Ketanserin	F _{5,75}	P=
		(mean ± SEM)	(mean ± SEM)	(mean ± SEM)	(mean ± SEM)	(mean ± SEM)	(mean ± SEM)		
Subjective effects									
Visual Analogue Scale (VAS, %max)									
Any drug effect	$\Delta E_{\max}$	0.9 ± 0.6	20 ± 3.8	57 ± 5.5	86 ± 5.7	83 ± 6.7	22 ± 4.9	72.9	<0.001
	AUEC	0.6 ± 0.4	58 ± 12	205 ± 32	431 ± 51	508 ± 82	133 ± 33	31.2	<0.001
Good drug effect	$\Delta E_{\max}$	1.1 ± 0.8	32 ± 6.8	59 ± 6.7	81 ± 6.9	82 ± 6.6	22 ± 6.8	43.3	<0.001
Bad drug effect	$\Delta E_{\max}$	0.1 ± 0.1	1.6 ± 0.8	1.5 ± 0.4	17 ± 5.9	28 ± 8.7	1.6 ± 0.6	8.82	<0.001
Drug liking	$\Delta E_{\max}$	0.8 ± 0.5	32 ± 7.5	60 ± 6.7	79 ± 8.1	76 ± 7.8	26 ± 7.2	29.5	<0.001
Stimulated	$\Delta E_{\max}$	0.1 ± 0.1	9.3 ± 3.3	40 ± 6.4	57 ± 10	66 ± 8.5	8.0 ± 2.4	27.8	<0.001
Fear	$\Delta E_{\max}$	0.0 ± 0.0	0.2 ± 0.1	1.2 ± 0.8	11 ± 6.7	15 ± 8.4	0.4 ± 0.3	2.85	<0.05
Ego dissolution	$\Delta E_{\max}$	0.0 ± 0.0	1.5 ± 0.7	21 ± 6.7	51 ± 9.6	73 ± 7.5	4.9 ± 3.7	35.6	<0.001
Concentration	$\Delta E_{\max}$	0.0 ± 0.0	0.3 ± 0.2	3.4 ± 2.1	11 ± 4.3	11 ± 4.6	1.8 ± 1.1	4.31	<0.01
	$\Delta E_{\min}$	-0.8 ± 0.7	-6.4 ± 2.1	-22 ± 3.6	-37 ± 4.8	-44 ± 2.9	-7.8 ± 2.1	50.9	<0.001
Sense of time	$\Delta E_{\max}$	0.1 ± 0.1	0.2 ± 0.1	0.7 ± 0.6	3.8 ± 3.0	13 ± 5.0	1.9 ± 1.6	4.54	<0.01
	$\Delta E_{\min}$	-0.1 ± 0.1	-5.4 ± 2.2	-25 ± 4.4	-32 ± 4.5	-41 ± 3.3	-3.4 ± 1.8	43.0	<0.001

	Pla - 25 µg	Pla - 50 µg	Pla - 100 µg	Pla - 200 µg	Pla - 200 µg +K	25 µg - 50 µg	25 µg - 100 µg	25 µg - 200 µg	25 µg - 200 µg + K	50 µg - 100 µg	50 µg - 200 µg	50 µg - 200 µg + K	100 µg - 200 µg	100 µg - 200 µg + K	200 µg - 200 µg + K
Subjective effects															
Visual Analogue Scale (VAS, %max)															
Any drug effect	*	***	***	***	*	***	***	***	NS	***	***	***	NS	***	***
AUEC	NS	**	***	***	NS	NS	***	***	NS	***	***	NS	NS	***	***
Good drug effect	***	***	***	***	*	**	***	***	NS	*	*	***	NS	***	***
Bad drug effect	NS	NS	*	***	NS	NS	NS	***	NS	NS	***	NS	NS	NS	***
Drug liking	***	***	***	***	*	*	***	***	NS	NS	NS	***	NS	***	***
Stimulated	NS	***	***	***	NS	**	***	***	NS	NS	*	***	NS	***	***
Fear	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
Ego dissolution	NS	*	***	***	NS	NS	***	***	NS	**	***	NS	*	***	***
Concentration	NS	NS	*	*	NS	NS	*	*	NS	NS	NS	NS	NS	NS	NS
$\Delta E_{\min}$	NS	***	***	***	NS	***	***	***	NS	**	***	**	NS	***	***
Sense of time	NS	NS	NS	**	NS	NS	NS	**	NS	NS	**	NS	NS	NS	*
$\Delta E_{\min}$	NS	***	***	***	NS	***	***	***	NS	NS	***	***	NS	***	***

*P<0.05, **P<0.01, ***P<0.001; NS, not significant; E_{max}, maximal effect; $\Delta E_{\max}$, maximaldifference from baseline; C_{max}, maximal concentration

SUBSTITUTE SHEET (RULE 26)

FIG. 7B

		Placebo	LSD 25 µg	LSD 50 µg	LSD 100 µg	LSD 200 µg	LSD 200 µg + Ketanserin	F _{5,75}	P=
		(mean ± SEM)	(mean ± SEM)	(mean ± SEM)	(mean ± SEM)	(mean ± SEM)	(mean ± SEM)		
5 Dimensions of Altered States of Consciousness (ASC) Scale									
Total ASC score	% score	0.1 ± 0.0	2.2 ± 0.6	9.5 ± 1.8	23 ± 2.9	30 ± 3.2	4.5 ± 1.5	52.0	<0.001
Oceanic boundlessness	% score	0.0 ± 0.0	2.9 ± 1.0	12 ± 2.8	28 ± 4.7	36 ± 5.1	4.1 ± 2.2	29.3	<0.001
Anxious ego-dissolution	% score	0.0 ± 0.0	0.6 ± 0.3	3.3 ± 1.1	11 ± 2.6	21 ± 5.4	1.1 ± 0.4	14.0	<0.001
Visionary restructuralization	% score	0.1 ± 0.0	3.1 ± 1.2	18 ± 4.1	43 ± 5.4	50 ± 4.7	7.4 ± 3.1	45.9	<0.001
Auditory alterations	% score	0.0 ± 0.0	0.4 ± 0.2	2.6 ± 1.0	9.1 ± 3.2	13 ± 3.3	2.5 ± 1.7	8.39	<0.001
Reductions of vigilance	% score	0.6 ± 0.2	4.5 ± 1.7	12 ± 2.3	24 ± 4.8	27 ± 4.7	10 ± 2.8	16.6	<0.001
Experience of unity	% score	0.0 ± 0.0	1.1 ± 0.7	10 ± 3.3	26 ± 6.0	40 ± 7.5	3.5 ± 2.6	17.4	<0.001
Spiritual experience	% score	0.0 ± 0.0	0.9 ± 0.9	4.9 ± 2.4	17 ± 4.5	18 ± 4.1	3.0 ± 1.8	10.9	<0.001
Blissful state	% score	0.1 ± 0.1	5.6 ± 1.8	18 ± 5.3	34 ± 7.8	33 ± 5.5	5.5 ± 2.6	10.5	<0.001
Insightfulness	% score	0.0 ± 0.0	3.4 ± 1.8	9.9 ± 3.4	30 ± 6.1	29 ± 5.6	2.2 ± 1.1	17.7	<0.001
Disembodiment	% score	0.0 ± 0.0	0.1 ± 0.1	3.6 ± 1.5	16 ± 5.8	37 ± 6.9	1.0 ± 0.6	16.9	<0.001
Impaired control and cognition	% score	0.1 ± 0.1	1.6 ± 0.8	6.6 ± 2.4	19 ± 3.5	27 ± 5.2	2.4 ± 1.0	23.3	<0.001
Anxiety	% score	0.0 ± 0.0	0.0 ± 0.0	0.5 ± 0.3	6.1 ± 3.0	17 ± 7.7	0.4 ± 0.3	4.51	<0.01
Complex imagery	% score	0.0 ± 0.0	4.3 ± 2.2	19 ± 6.6	53 ± 8.2	62 ± 8.1	8.8 ± 3.7	28.5	<0.001
Elementary imagery	% score	0.4 ± 0.3	2.6 ± 1.2	25 ± 6.9	50 ± 5.9	68 ± 6.6	14 ± 6.8	26.8	<0.001
Audio-visual synesthesia	% score	0.0 ± 0.0	3.1 ± 1.6	25 ± 6.8	58 ± 8.4	70 ± 7.6	12 ± 5.2	28.5	<0.001
Changed meaning of percepts	% score	0.0 ± 0.0	1.3 ± 0.6	12 ± 3.5	26 ± 8.0	30 ± 5.5	2.6 ± 1.3	12.9	<0.001

	Pla - 25 µg	Pla - 50 µg	Pla - 100 µg	Pla - 200 µg	Pla - 200 µg +K	25 µg - 50 µg	25 µg - 100 µg	25 µg - 200 µg	25 µg - 200 µg K	50 µg - 100 µg	50 µg - 200 µg	50 µg - 200 µg K	100 µg - 200 µg	100 µg - 200 µg K	200 µg - 200 µg K
5 Dimensions of Altered States of Consciousness (ASC) Scale															
Total ASC score	NS	**	***	***	NS	*	***	***	NS	***	***	NS	NS	***	***
Oceanic boundlessness	NS	*	***	***	NS	NS	***	***	NS	***	***	NS	NS	***	***
Anxious ego-dissolution	NS	NS	**	***	NS	NS	*	***	NS	NS	***	NS	*	*	***
Visionary restructuralization	NS	**	***	***	NS	*	***	***	NS	***	***	NS	NS	***	***
Auditory alterations	NS	NS	**	***	NS	NS	*	***	NS	NS	**	NS	NS	NS	**
Reductions of vigilance	NS	*	***	***	NS	NS	***	***	NS	*	**	NS	NS	**	***
Experience of unity	NS	NS	***	***	NS	NS	***	***	NS	*	***	NS	NS	**	***
Spiritual experience	NS	NS	***	***	NS	NS	***	***	NS	*	**	NS	NS	**	***
Blissful state	NS	NS	***	***	NS	NS	***	***	NS	NS	NS	NS	NS	***	***
Insightfulness	NS	NS	***	***	NS	NS	***	***	NS	***	**	NS	NS	***	***
Disembodiment	NS	NS	*	***	NS	NS	*	***	NS	NS	***	NS	**	*	***
Impaired control and cognition	NS	NS	***	***	NS	NS	***	***	NS	**	***	NS	NS	***	***
Anxiety	NS	NS	NS	**	NS	NS	NS	**	NS	NS	**	NS	NS	NS	**
Complex imagery	NS	NS	***	***	NS	NS	***	***	NS	***	***	NS	NS	***	***
Elementary imagery	NS	*	***	***	NS	*	***	***	NS	*	***	NS	NS	***	***
Audio-visual synesthesia	NS	*	***	***	NS	NS	***	***	NS	**	***	NS	NS	***	***
Changed meaning of percepts	NS	NS	***	***	NS	NS	***	***	NS	NS	*	NS	NS	***	***

*P<0.05, **P<0.01, ***P<0.001; NS, not significant; E_{max}, maximal effect; ΔE_{max}, maximal difference from baseline; C_{max}, maximal concentration

SUBSTITUTE SHEET (RULE 26)

9/23

FIG. 7C

FIG. 7C

		Placebo	LSD 25 µg	LSD 50 µg	LSD 100 µg	LSD 200 µg	LSD 200 µg + Ketanserin	F _{5,75}	P=
		(mean ± SEM)	(mean ± SEM)	(mean ± SEM)	(mean ± SEM)	(mean ± SEM)	(mean ± SEM)		
Mystical Effects Questionnaire (MEQ43)									
Internal unity	% score	0.0 ± 0.0	3.8 ± 1.6	14 ± 4.2	28 ± 6.3	38 ± 6.7	7.5 ± 3.7	16.3	<0.001
External unity	% score	0.0 ± 0.0	3.3 ± 1.9	12.7 ± 3.7	26 ± 5.2	33 ± 5.3	9.8 ± 4.0	18.4	<0.001
Sacredness	% score	0.0 ± 0.0	6.3 ± 2.4	19.1 ± 4.7	30 ± 6.5	34 ± 6.4	11 ± 4.8	12.1	<0.001
Noetic quality	% score	1.3 ± 1.3	8.1 ± 3.7	15 ± 3.6	35 ± 6.6	27 ± 5.3	6.6 ± 3.2	16.4	<0.001
Deeply felt positive mood	% score	0.0 ± 0.0	16 ± 4.1	30 ± 5.7	39 ± 5.9	44 ± 6.4	16 ± 5.6	16.1	<0.001
Transcendence of time/space	% score	0.0 ± 0.0	6.3 ± 2.0	25 ± 5.0	46 ± 6.5	61 ± 7.0	11 ± 4.4	37.0	<0.001
Ineffability	% score	0.0 ± 0.0	9.5 ± 4.1	32 ± 5.7	52 ± 4.9	61 ± 5.2	15 ± 5.7	40.3	<0.001
Mystical Effects Questionnaire (MEQ30)									
Mystical	% score	0.3 ± 0.3	4.4 ± 2.0	14.8 ± 4.2	28 ± 6.4	32 ± 5.7	8.1 ± 3.8	14.4	<0.001
Positive mood	% score	0.0 ± 0.0	18 ± 4.0	31 ± 5.2	42 ± 5.5	45 ± 6.4	17 ± 5.9	18.8	<0.001
Transcendence of time/space	% score	0.0 ± 0.0	7.3 ± 2.2	26 ± 4.9	47 ± 6.0	61 ± 6.9	11 ± 4.3	39.9	<0.001
Ineffability	% score	0.0 ± 0.0	13 ± 5.3	45 ± 7.1	71 ± 5.8	78 ± 6.0	19 ± 6.7	39.6	<0.001
MEQ30 total score	% score	0.2 ± 0.2	8.5 ± 2.4	23 ± 4.4	39 ± 5.3	45 ± 5.4	12 ± 4.4	30.5	<0.001
Nadir	% score	0.0 ± 0.0	1.4 ± 0.6	7.6 ± 2.5	14 ± 3.6	26 ± 6.8	4.3 ± 1.6	11.8	<0.001
Aesthetic Experience	% score	0.5 ± 0.3	8.5 ± 2.78	28 ± 5.2	46 ± 5.8	48 ± 5.7	17 ± 4.2	27.4	<0.001

	Pla - 25 µg	Pla - 50 µg	Pla - 100 µg	Pla - 200 µg	Pla - 200 µg +K	25 µg - 50 µg	25 µg - 100 µg	25 µg - 200 µg	25 µg - 200 µg +K	50 µg - 100 µg	50 µg - 200 µg	50 µg - 200 µg +K	100 µg - 200 µg	100 µg - 200 µg +K	200 µg - 200 µg +K
Mystical Effects Questionnaire (MEQ43)															
Internal unity	NS	NS	***	***	NS	NS	***	***	NS	NS	***	NS	NS	**	***
External unity	NS	*	***	***	NS	NS	***	***	NS	*	***	NS	NS	**	***
Sacredness	NS	**	***	***	NS	NS	***	***	NS	NS	NS	NS	NS	*	**
Noetic quality	NS	*	***	***	NS	NS	***	**	NS	***	NS	NS	NS	***	***
Deeply felt positive mood	NS	***	***	***	NS	NS	**	***	NS	NS	NS	NS	NS	**	***
Transcendence of time/space	NS	***	***	***	NS	*	***	***	NS	**	***	NS	NS	***	***
Ineffability	NS	***	***	***	NS	**	***	***	NS	**	***	*	NS	***	***
Mystical Effects Questionnaire (MEQ30)															
Mystical	NS	*	***	***	NS	NS	***	***	NS	NS	**	NS	NS	**	***
Positive mood	*	***	***	***	*	NS	***	***	NS	NS	NS	NS	NS	***	***
Transcendence of time/space	NS	***	***	***	NS	**	***	***	NS	**	***	NS	NS	***	***
Ineffability	NS	***	***	***	NS	***	***	***	NS	**	***	**	NS	***	***
MEQ30 total score	NS	***	***	***	NS	*	***	***	NS	*	***	NS	NS	***	***
Nadir	NS	NS	**	***	NS	NS	*	***	NS	NS	***	NS	*	NS	***
Aesthetic Experience	NS	***	***	***	*	**	***	***	NS	*	**	NS	NS	***	***

*P<0.05, **P<0.01, ***P<0.001; NS, not significant; E_{max}, maximal effect; ΔE_{max}, maximal difference from baseline; C_{max}, maximal concentration

SUBSTITUTE SHEET (RULE 26)

FIG. 7D

		Placebo	LSD 25 µg	LSD 50 µg	LSD 100 µg	LSD 200 µg	LSD 200 µg + Ketanserin	F _{8,75}	P=
		(mean ± SEM)	(mean ± SEM)	(mean ± SEM)	(mean ± SEM)	(mean ± SEM)	(mean ± SEM)		
Adjective Mood Rating Scale (AMRS score)									
Well-being	ΔE _{max}	0.5 ± 0.3	2.6 ± 0.8	4.1 ± 1.0	3.1 ± 1.2	4.0 ± 1.3	2.3 ± 0.8	2.41	<0.05
Anxiety	ΔE _{max}	0.0 ± 0.1	0.3 ± 0.1	0.2 ± 0.2	1.0 ± 0.5	1.8 ± 0.7	0.2 ± 0.2	4.07	<0.01
Inactivity	ΔE _{max}	2.9 ± 0.8	4.3 ± 1.1	6.4 ± 1.0	9.4 ± 2.0	9.6 ± 1.6	5.4 ± 1.3	6.27	<0.001
Extraversion	ΔE _{max}	0.1 ± 0.2	0.8 ± 0.4	0.5 ± 0.4	0.5 ± 0.4	0.8 ± 0.5	0.2 ± 0.3	0.74	NS
Introversion	ΔE _{max}	0.6 ± 0.3	0.8 ± 0.4	3.0 ± 0.7	4.8 ± 1.1	4.3 ± 0.9	1.9 ± 0.6	11.6	<0.001
Emotional excitation	ΔE _{max}	-0.6 ± 0.3	-0.2 ± 0.4	0.9 ± 0.8	5.8 ± 1.9	5.4 ± 1.2	0.1 ± 0.5	9.25	<0.001
Autonomic effects									
Systolic blood pressure (mmHg)	E _{max}	131 ± 3.5	133 ± 3.0	137 ± 3.2	139 ± 3.5	138 ± 2.4	133 ± 3.0	5.05	<0.001
	E _{min}	110 ± 2.7	113 ± 2.9	115 ± 2.3	113 ± 2.9	117 ± 2.2	109 ± 3.0	6.77	<0.001
Diastolic blood pressure (mmHg)	E _{max}	80 ± 2.1	83 ± 1.7	84 ± 1.9	85 ± 2.0	87 ± 2.0	83 ± 1.8	4.76	<0.001
	E _{min}	64 ± 1.7	65 ± 1.7	67 ± 1.7	66 ± 1.7	69 ± 1.5	63 ± 1.8	6.57	<0.001
Heart rate (beats/min)	E _{max}	75 ± 2.7	76 ± 2.6	79 ± 2.1	83 ± 3.3	86 ± 3.9	77 ± 3.3	9.59	<0.001
Body temperature (°C)	E _{max}	37.3 ± 0.1	37.3 ± 0.07	37.4 ± 0.08	37.5 ± 0.09	37.5 ± 0.1	37.3 ± 0.09	2.17	NS
List of Complaints (LC score)									
Acute adverse effects	0-12 h	1.6 ± 0.8	4.0 ± 1.0	6.1 ± 1.4	12 ± 2.5	13.5 ± 3.3	4.6 ± 1.1	10.8	<0.001
Subacute adverse effects	12-24 h	0.3 ± 0.3	0.8 ± 0.3	2.2 ± 1.6	5.9 ± 2.3	4.5 ± 1.9	4.4 ± 1.9	3.69	<0.01
Adverse Effects	E _{max}	1.7 ± 0.8	4.0 ± 1.0	6.8 ± 1.8	13 ± 2.5	14 ± 3.3	6.2 ± 1.8	11.0	<0.001
BDNF (pg/mL)	C _{max}	2953 ± 484	3800 ± 617	3561 ± 464	3848 ± 723	5685 ± 693	4372 ± 880	2.61	<0.05

	Pla	Pla	Pla	Pla	Pla	25	25	25	25	50	50	50	100	100	200
	-	-	-	-	200	µg -	µg -	µg -	µg -	µg -	µg -	µg -	µg -	µg -	µg -
	25	50	100	200	µg	50	100	200	200	100	200	200	200	200	200
	µg	µg	µg	µg	+K	µg	µg	µg	µg+	µg	µg	µg	µg+	µg+	µg+

Adjective Mood Rating Scale (AMRS score)															
Well-being	NS	*	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
Anxiety	NS	NS	NS	**	NS	NS	NS	*	NS	NS	*	NS	NS	NS	*
Inactivity	NS	NS	***	***	NS	NS	*	*	NS	NS	NS	NS	NS	NS	NS
Extraversion	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
Introversion	NS	*	***	***	NS	*	***	***	NS	NS	NS	NS	NS	**	*
Emotional excitation	NS	NS	***	***	NS	NS	***	**	NS	**	*	NS	NS	**	**
Autonomic effects															
Systolic blood pressure (mmHg)	NS	*	**	*	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
	E _{min}	NS	NS	NS	**	NS	NS	NS	NS	NS	NS	**	NS	NS	***
Diastolic blood pressure (mmHg)	NS	NS	*	***	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
	E _{max}	NS	NS	NS	**	NS	NS	NS	*	NS	NS	NS	**	NS	*
Heart rate (beats/min)	NS	NS	**	***	NS	NS	*	***	NS	NS	**	NS	NS	NS	***
Body temperature (°C)	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
List of Complaints (LC score)															
Acute adverse effects	NS	NS	***	***	NS	NS	**	***	NS	*	**	NS	NS	**	***
Subacute adverse effects	NS	NS	*	NS	NS	NS	*	NS	NS	NS	NS	NS	NS	NS	NS
Adverse Effects	NS	NS	***	***	NS	NS	***	***	NS	*	*	NS	NS	*	**
BDNF (pg/mL)	NS	NS	NS	*	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS

*P<0.05, **P<0.01, ***P<0.001; NS, not significant; E_{max}, maximal effect; ΔE_{max}, maximal difference from baseline; C_{max}, maximal concentration

SUBSTITUTE SHEET (RULE 26)

FIG. 8A




FIG. 8B




FIG. 8C




FIG. 9




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D




FIG. 11

Acute adverse drug effects

	LSD 25 µg			LSD 50 µg			LSD 100 µg		
	0h	0-12h	12-24h	0h	0-12h	12-24h	0h	0-12h	12-24h
Tiredness	4	4	7	7	6	7	5	7	8
Headache	1	6	4	1	5	4	0	10	9
Lack of concentration	0	7	1	0	6	1	0	11	5
Lack of appetite	0	3	0	0	3	0	0	8	3
Dullness	0	4	1	1	3	2	0	5	4
Brooding	0	2	0	0	3	1	0	7	6
Dry mouth	1	2	2	0	3	3	0	4	2
Feeling of weakness	0	3	0	0	3	2	0	7	3
Uneasiness	0	1	0	1	4	1	0	9	2
Hypersensitivity to certain odours	0	2	0	0	4	2	0	5	2
Lack of energy	1	3	0	0	2	1	0	6	3
Abdominal pain	0	3	0	0	4	1	0	4	1
Obliviousness	0	1	0	0	3	2	0	5	4
Crying tendency	0	1	0	0	1	1	0	5	4
Nausea	0	2	0	0	0	0	0	5	1
Rapid exhaustibility	0	0	0	0	2	1	0	6	2
Dizziness	0	3	0	0	1	1	0	5	2
Excessive urge to urinate	0	2	1	0	2	1	0	3	1
Feel of pressure or fullness	0	0	0	0	3	0	0	3	1
Imbalance	0	1	0	0	0	1	0	7	1
	LSD 200 µg			LSD 200 µg + Ketanserin			Placebo		
	0h	0-12h	12-24h	0h	0-12h	12-24h	0h	0-12h	12-24h
Tiredness	4	5	7	6	11	9	5	8	4
Headache	0	5	4	1	5	5	0	3	3
Lack of concentration	0	8	3	1	7	3	0	2	0
Lack of appetite	0	8	1	0	4	2	0	1	0
Dullness	0	4	3	1	2	3	0	1	1
Brooding	1	4	3	0	2	4	0	1	0
Dry mouth	0	4	2	0	3	3	0	3	1
Feeling of weakness	0	5	2	0	2	3	0	0	0
Uneasiness	0	5	2	0	2	4	0	0	0
Hypersensitivity to certain odours	0	6	2	0	3	2	0	1	0
Lack of energy	0	3	2	1	4	3	0	1	0
Abdominal pain	1	3	2	0	3	3	0	2	0
Obliviousness	0	5	2	0	0	2	0	0	0
Crying tendency	0	5	3	0	1	2	0	0	0
Nausea	0	5	3	0	3	1	0	2	1
Rapid exhaustibility	0	5	3	1	1	2	0	0	0
Dizziness	0	3	0	0	4	1	0	0	0
Excessive urge to urinate	0	2	2	0	4	1	0	0	1
Feel of pressure or fullness	0	5	2	0	2	3	0	1	0
Imbalance	0	6	1	0	2	1	0	0	0

Data indicate number of subjects reporting an effect among a total of 16 subjects.

FIG. 12

Pharmacokinetic parameters for different doses
of LSD based on compartmental modeling

Dose (μg)			K ₀₁ (1/h)	λ _z (1/h)	V _d /F (L)	C _{max} (ng/mL)
LSD	25	Geometric mean (95% CI)	2.0 (1.3-3.2)	0.19 (0.16-0.24)	38 (30-47)	0.49 (0.41-0.58)
		Range	0.40-15.1	0.06-0.35	15-102	0.20-0.71
	50	Geometric mean (95% CI)	2.1 (1.5-3.0)	0.19 (0.16-0.23)	35 (31-38)	1.1 (0.99-1.2)
		Range	0.43-19.8	0.06-0.44	22-46	0.68-1.6
	100	Geometric mean (95% CI)	1.8 (1.4-2.4)	0.18 (0.15-0.21)	37 (33-42)	2.0 (1.9-2.2)
		Range	0.7-4.5	0.06-0.24	22-51	1.7-2.9
	200	Geometric mean (95% CI)	1.6 (1.2-2.1)	0.17 (0.14-0.20)	39 (35-43)	3.9 (3.5-4.3)
		Range	0.45-5.03	0.06-0.35	25-67	2.5-6.0
	200 + Ketanserin	Geometric mean (95% CI)	2.3 (1.4-3.8)	0.15 (0.13-0.18)	36 (32-40)	4.4 (4.0-4.8)
		Range	0.6-20.0	0.06-0.24	23-47	3.1-6.8
			t _{max} (h)	t _{1/2} (h)	AUC _∞ (ng·h/mL)	CL/F (L/h)
	25	Geometric mean (95% CI)	1.2 (0.9-1.7)	3.6 (2.9-4.4)	3.5 (2.7-4.5)	7.2 (5.6-9.3)
		Range	0.29-2.7	2.0-12	1.1-12	2.0-22
	50	Geometric mean (95% CI)	1.2 (0.95-1.6)	3.6 (3.0-4.2)	7.4 (6.2-8.9)	6.7 (5.6-8.0)
		Range	0.25-2.5	1.6-11	4.2-25	2.0-11.8
	100	Geometric mean (95% CI)	1.4 (1.2-1.7)	3.9 (3.2-4.7)	15 (12-18)	6.6 (5.4-8.0)
		Range	0.74-2.5	2.9-12	11-47	2.1-9.4
	200	Geometric mean (95% CI)	1.5 (1.3-1.9)	4.1 (3.4-4.9)	31 (25-38)	6.5 (5.3-8.0)
		Range	0.70-5.0	2.0-11	18-127	1.6-11
	200 + Ketanserin	Geometric mean (95% CI)	1.2 (0.85-1.8)	4.5 (3.8-5.3)	36 (30-43)	5.6 (4.6-6.8)
		Range	0.25-4.1	0.25-4.1	25-110	1.8-7.9

AUC_{∞} , area under the plasma concentration-time curve from time zero to infinity; CL/F apparent total clearance; $C_{\max}$, estimated maximum plasma concentration; $t_{1/2}$, estimated plasma elimination half-life; $t_{\max}$, estimated time to reach $C_{\max}$; k_{01} , first-order absorption coefficient; λ_z , first order elimination coefficient; V_z/F volume of distribution.

SUBSTITUTE SHEET (RULE 26)

FIG. 13

Drug dose identification after each session and after the study

	LSD 200 µg		LSD 100 µg		LSD 50 µg	
	after Session	after Study	after Session	after Study	after Session	after Study
correctly identified	56%	63%	44%	69%	50%	63%
missclassified as LSD 200 µg			44%	19%	0%	6%
missclassified as LSD 100 µg	38%	31%			25%	0%
missclassified as LSD 50 µg	0%	6%	13%	6%		
missclassified as LSD 25 µg	6%	0%	0%	6%	19%	6%
missclassified as LSD 200 µg + ketanserin	0%	0%	0%	0%	6%	13%
missclassified as placebo	0%	0%	0%	0%	0%	13%
	LSD 25 µg		LSD 200 µg + Ketanserin		Placebo	
	after Session	after Study	after Session	after Study	after Session	after Study
correctly identified	56%	63%	56%	75%	81%	69%
missclassified as LSD 200 µg	0%	0%	0%	0%	0%	6%
missclassified as LSD 100 µg	0%	0%	0%	0%	0%	6%
missclassified as LSD 50 µg	31%	13%	19%	6%	0%	6%
missclassified as LSD 25 µg			19%	13%	13%	13%
missclassified as LSD 200 µg + ketanserin	6%	6%			6%	0%
missclassified as placebo	6%	13%	6%	6%		

FIG.14A




FIG.14B





FIG.14C



SUBSTITUTE SHEET (RULE 26)

FIG.14D




FIG.14E





FIG.14F



SUBSTITUTE SHEET (RULE 26)

FIG. 14G




FIG. 14H






FIG. 14I



SUBSTITUTE SHEET (RULE 26)

FIG.15



SUBSTITUTE SHEET (RULE 26)

FIG.16A




FIG.16B




FIG.16C




FIG.16D

